Skip Navigation

Neuro-Oncology 2009 11(2):183-191; doi:10.1215/15228517-2008-076
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kozak, K. R.
Right arrow Articles by Moody, J. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kozak, K. R.
Right arrow Articles by Moody, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome

Kevin R. Kozak, Anand Mahadevan and John S. Moody

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI (K.R.K.), Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA (A.M.), Department of Radiation Oncology, University of Alabama School of Medicine, Birmingham, AL, (J.S.M.); USA

Address correspondence to Kevin R. Kozak, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4/362 CSC, 600 Highland Ave., Madison, WI 53792, USA (kozak{at}humonc.wisc.edu).


  Abstract

The epidemiology and natural history of adult gliosarcomas (GSMs), as well as patient and treatment factors associated with outcome, are ill defined. Patients over 20 years of age with GSM diagnosed from 1988 to 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival analysis and Cox models were used to examine outcomes. Similar analyses were conducted for patients diagnosed with glioblastoma (GBM) over the same time period. GSM represented 2.2% of the 16,388 patients identified with either GSM or GBM. No significant differences between GSM and GBM were identified with respect to age, gender, race, tumor size, or use of adjuvant radiation therapy (RT). Patients with GSM were more likely to have temporal lobe involvement and undergo some form of tumor resection. The most important analyzed factors influencing GSM overall survival were age, extent of resection, and use of adjuvant RT. After adjusting for factors impacting overall survival, the prognosis for GSM appears slightly worse than for GBM (HR = 1.17, 95% CI, 1.05–1.31). GSM is a rare malignancy that presents very similarly to GBM with a slightly greater propensity for temporal lobe involvement. Optimal treatment remains to be defined. However, these retrospective findings suggest tumor excision, as opposed to biopsy only, and adjuvant RT may improve outcome. Despite therapy, prognosis remains dismal and outcomes may be inferior to those seen in GBM patients.

Keywords: glioblastoma, gliosarcoma, radiation, SEER

Received March 11, 2008; Accepted April 16, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.